Postdoctoral Fellow-MSH-12300-127

The Mount Sinai School of Medicine has a Post-Doctoral Fellow opening immediately available in the laboratory of Dr. Joshua Brody – Director, Lymphoma Immunotherapy Program. This individual will perform a wide variety of moderately complex laboratory tasks/experiments, and maintain lab equipment and inventory levels of supplies.

Responsibilities of this position involve designing protocols and carrying out experiments, interpreting results, and preparing figures to convey analyses. Experimental duties will include but are not limited to performing cellular and molecular immunology techniques such as Flow Cytometry, ELISA, Luminex, and studies with animals as well as primary patient specimens. 

The lab will provide the chance to learn novel aspects of basic and tumor immunology, multi-parametric flow cytometry and phospho-flow signaling studies, animal techniques including bone marrow transplantation, anti-tumor vaccinations, and a large variety of functional assessments of anti-tumor T cell induction. 

Our lab has the rare opportunity to both perform correlative studies on primary patient tumor samples from early phase clinical trials and to continually develop advancements in those trials based on what is learned. The core mission is the translation of basic science in tumor immunology into novel and rapidly accruing clinical trials as exemplified in recent high-impact publications: 

Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, Kim K, Aleynick M, Hammerich L, Upadhyay R, Yellin M, Marsh H, Oreper D, Jhunjhunwala S, Moussion C, Merad M, Brown BD, García-Sastre A, Brody JD   Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.  Nat Commun. 2022 Nov 22;13(1):7149. 

Anagnostou T, Brody JD.  In CAR T cell-treated lymphomas, the T cell rich get richer.  Nat Med. 2022 Sep;28(9):1757-58. 

Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. Cancer vaccines: the next immunotherapy frontier.  Nat Cancer. 2022 Aug;3(8):911-926. 

Lubitz GS, Brody JD. Not just neighbours: positive feedback between tumour-associated macrophages and exhausted T cells.  Nat Rev Immunol. 2022 Jan;22(1):3. 

Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, Bhalla S, Scholler N, Bot A, Rossi JM, Sadek N, Parekh S, Lagana A, Baccarini A, Merad M, Brown BD, Brody JD.  A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discov. 2021 Mar;11(3):599-613. doi: 10.1158/2159-8290.CD-20-0756. 

Marshall N, Hutchinson K, Marron TU, Aleynick M, Hammerich L, Upadhyay R, Svensson-Arvelund J, Brown BD, Merad M, Brody JD. Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade. Cancer Discov. 2019 Nov;9(11):1520-1537.  

Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, Zhan Y, Ostrowski D, Yellin M, Marsh H, Salazar AM, Rahman AH, Brown BD, Merad M, Brody JD. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.  Nat Med. 2019 May;25(5):814-824.